We are building a position in Novo Nordisk, seeing strong long-term value in its leadership of the fast-growing GLP-1 analogues market. Recent stock declines stem from correctable missteps and ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy. Skip to content.

Novo Nordisk A/S (NYSE:NVO) is one of the 17 stocks that Jim Cramer commented on. During the episode, Cramer said that he prefers Eli Lilly to Novo Nordisk A/S (NYSE:NVO).

[COPENHAGEN] Novo Nordisk reclaimed its position as Europe’s most valuable public company, overtaking software developer SAP. Shares in the Danish drugmaker climbed as much as 2.3 per cent on Friday ...

Pharmaceutical giant Novo Nordisk today announced a significant step forward in its fight against obesity, revealing plans to advance both subcutaneous and oral formulations of its novel drug, ...

Novo Nordisk is planning Phase 3 clinical trials for a obesity drug combination called amycretin, adding another emerging weight-loss medicine to the list of prospects it has in advanced testing. The ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs ...

The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish ...

(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the ...